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Abstract 
 
Background: There is a need to better define the epidemiology of sepsis in ICUs around the globe.  
Methods: The ICON (Intensive Care over Nations) audit prospectively collected data on all adult (>16 
years) patients admitted to the ICU between May 8 and May 18, 2012, except those admitted for less 
than 24 hours for routine postoperative surveillance. Data were collected daily for a maximum of 28 
days in the ICU and patients were followed up for outcome data until death, hospital discharge, or 
for 60 days. Participation was entirely voluntary. 
Results: The audit included 10,069 patients from Europe (54.1%), Asia (19.2%), America (17.1%) and 
other continents (9.6%). Sepsis, defined as infection with associated organ failure, was identified 
during the ICU stay in 2,973 (29.5%) patients, including in 1,808 (18.0%) already at ICU admission. 
Occurrence rates of sepsis varied from 13.6% to 39.3% in the different regions. Overall ICU and 
hospital mortality rates were 25.8% and 35.3%, respectively, in patients with sepsis, but varied from 
11.9% and 19.3% (Oceania) to 39.5% and 47.2% (Africa), respectively. After adjustment for possible 
confounders in a multilevel analysis, independent risk factors for in-hospital death included older 
age, higher SAPS II score, comorbid cancer, chronic heart failure (NYHA III/IV), cirrhosis, use of 
mechanical ventilation or renal replacement therapy and infection with Acinetobacter spp. 
Conclusions: Sepsis remains a major health problem in ICU patients worldwide, associated with high 
mortality rates. However, there is wide variability in the sepsis rate and outcomes in ICU patients 
around the globe. 
 
Key words: septic shock; international; critically ill; mortality  
 
Key points: 
 Sepsis is a major health problem which occurs in up to 39% of ICU patients 
 In this worldwide audit, substantial variations in the epidemiology and outcome of sepsis 
were observed 
 ICU mortality rate in patients with sepsis was 26%, twice as high as in non-septic patients. 
Hospital mortality rates were reported to be as high as 47% in some geographic regions 
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 Independent risk factors for in-hospital death included older age, higher disease severity, 
comorbidities, and use of organ support 
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Introduction 
Sepsis is a major cause of morbidity and mortality in modern intensive care units (ICUs). Although a 
number of studies have provided epidemiological data on sepsis in ICU patients in the developed 
world [1-6], there is limited information on the global burden of sepsis worldwide [7, 8]. Yet, such 
data are crucially important to increase awareness of the global impact of sepsis, to highlight the need 
for continued research into potential preventive and therapeutic interventions, and to help guide 
resource allocation [9]. Information on patterns of sepsis around the globe is also of interest, including 
causative microorganisms, primary source of infection, and associated outcomes.   
 In 2012, the World Federation of Societies of Intensive and Critical Care Medicine 
(WFSICCM) conducted a worldwide audit of data from ICUs around the world, providing a large 
database from which to extract information. We used these data to explore the characteristics of 
patients with sepsis around the world, including international differences in occurrence rates, causative 
microorganisms and outcomes. We also evaluated some f ctors associated with in-hospital mortality 
in these patients.   
 
Methods 
The worldwide Intensive Care over Nations (ICON) audit recruited ICUs by open invitation, through 
national scientific soci ties, national and international meetings, email lists and individual contacts. 
Participation was entirely voluntary, with no financial incentive. Ethics committee approval was 
obtained by the participating institutions according to local ethical regulations. Informed consent 
was not required for this observational and anonymous audit. Of the 730 ICUs contributing to the 
study from 84 countries (see the participants list in Appendix 1), 419 (57.4%) were in 
university/academic hospitals. The organizational characteristics of these centres have been 
described previously [10].  
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 Each ICU was asked to prospectively collect data on all adult (>16 years) patients admitted to 
their ICU between May 8 and May 18, 2012, except those who stayed in the ICU for <24 hours for 
routine postoperative surveillance. Re-admissions of previously included patients were not included. 
Data were collected daily for a maximum of 28 days in the ICU. Outcome data were collected at the 
time of ICU and hospital discharge, or at 60 days. Data were entered anonymously using electronic 
case report forms (CRFs) via a secured internet-based website. Data collection on admission included 
demographic data and comorbidities. Clinical and laboratory data for SAPS II [11] and APACHE II [12] 
scores were reported as the worst values within the first 24 hours after admission. A daily evaluation 
of organ function was performed according to the sequential organ failure assessment (SOFA) score 
[13]; organ failure was defined as a SOFA subscore >2 for the organ in question. Clinical and 
microbiologic infections were reported daily as well as antimicrobial therapy. 
Infection was defined according to the criteria of the International Sepsis Forum [14]. Sepsis 
was defined as the presence of infection with associated organ failure [15]. Septic shock was defined 
as sepsis associated with cardiovascular failure requiring vasopressor support (SOFA cardiovascular 
of 3 or 4). ICU-acquired infection was defined as infection identified at least 48 hours after ICU 
admission. Non-ICU acquired infection was defined as infection present on admission or within the 
first 48 hours after ICU admission. Only the first episode of infection was considered in the analysis. 
 Detailed instructions and definitions were available through a secured website for all 
participants before starting data collection and throughout the study period. Any additional queries 
were answered on a per case basis. Validity checks were made at the time of electronic data entry, 
including plausibility checks within each variable and between variables. Data were further reviewed 
by the coordinating centre for completeness and plausibility, and any doubts were clarified with the 
participating centre. There was no on-site monitoring. We did not attempt to verify the pathogenicity 
of the microorganisms, including the relevance of Staphylococcus epidermidis or the distinction 
between colonization and infection.  
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For the purposes of this audit, we divided the world into 8 geographic regions: 
North America, South America, Western Europe, Eastern Europe, South Asia, East 
and South-East Asia, Oceania and Africa. Individual countries were also classified 
into three income groups according to the 2011 gross national income (GNI) per 
capita, calculated using the World Bank Atlas method [16]: GNI < $4,035 = low and 
lower middle income; GNI $4,036–12,475 = upper middle income; and GNI >$12,476 
= high income. 
 
Statistical analysis 
Data are shown as means with standard deviation (SD), mean and 95% confidence 
intervals (CI), medians and interquartile ranges (IQ), numbers and percentages. 
Differences between groups in distribution of variables were assessed using analysis 
of variance (ANOVA), Kruskal Wallis test, Student’s t-test, Mann-Whitney test, chi-
square test or Fisher’s exact test as appropriate.  
 To identify the risk factors associated with in-hospital mortality in septic 
patients we used a three-level multilevel technique with the structure of an individual 
patient (level 1) admitted to a hospital (level 2) within a country (level 3). The 
explanatory variables considered in the model were: 
- Individual-level factors: age, sex, SAPS II score, type of admission, source of 
admission, mechanical ventilation or renal replacement therapy at any time during 
the ICU stay, comorbidities, onset of infection, site of infection and the most common 
microorganisms. 
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- Hospital-level factors: type of hospital; ICU specialty; total number of ICU 
patients in 2011; number of staffed ICU beds. 
- Country-level factors: GNI. 
Individual-level variables to be included in the final model were selected on the basis 
of a multilevel model including country-level and hospital-level factors and each of 
the individual-level factors; variables with a p-value <0.2 were considered in the final 
model. Collinearity between variables was checked by inspection of the correlation 
between them, by looking at the correlation matrix of the estimated parameters, and 
by looking at the change of parameter estimates and at their estimated standard 
errors [17]. Q-Q plots were drawn to check for normality in the residuals. The results 
of fixed effects (measures of association) are given as odds ratios (OR) with their 
95% confidence intervals and the 80% interval OR (IOR-80). Random effects 
(measures of variation) measures included the variance (var) and its standard error 
(se) and the median odds ratio (MOR). The statistical significance of covariates was 
calculated using the Wald test. 
 Data were analyzed using IBM® SPSS® Statistics software, version 22 for 
Windows and R software, version 2.0.1 (CRAN project). All reported p-values are 
two-sided and a p-value <0.05 was considered to indicate statistical significance. The 
results of fixed effects are given as OR with 95% confidence intervals.  
 
Results 
Characteristics of the study group  
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A total of 10,069 patients were included in the audit; 2,973 patients (29.5%) had sepsis, including 
1,808 (18.0%) with sepsis at admission to the ICU (Figure 1). In the whole cohort, antimicrobials were 
given to 5,975 (59.3%) patients during their ICU stay. Patients with sepsis were older, had higher 
severity scores on admission to the ICU, had more comorbidities and were more commonly receiving 
mechanical ventilation and renal replacement therapy on admission to the ICU than patients without 
sepsis (Table 1). Patients with sepsis also had more organ failures than the other patients (3 [1-4] vs. 
1 [0-2] organs, p<0.001). 
 
Patterns of infections 
The most common source of sepsis was the respiratory tract (67.4%) followed by the abdomen 
(21.8%) (Table E1). Positive isolates were retrieved in 69.6% (n=2,069) of patients with sepsis; two 
thirds of these patients had Gram-negative microorganisms isolated and half had Gram-positive 
microorganisms; 1068 (51.6%) of the sepsis patients with positive isolates had more than one 
microorganism isolated (Table 2). Patients with urinary tract (82.6% vs 43.9%), abdominal (77.1% vs 
50.8%) and respiratory tract (70.0% vs 51.4%) infections were more likely to have Gram-negative 
than Gram-positive isolates (Table E1). Microbiological patterns varied around the globe (Table 2), 
with Gram-positive isolates being much less frequent (21.4%) in South Asia than in other regions. 
Methicillin-resistant Staphylococcus aureus (MRSA) was more common in the Middle East (14.4%) 
and North America (12.8%) than in Western Europe (6.1%). Klebsiella spp. isolates were most 
commonly reported in Africa (31.3%), Eastern Europe (28.5%), and South America (24.7%), and 
Pseudomonas spp. was most frequent in Eastern Europe (21.1%) and South America (20.4%). Fungal 
organisms contributed to 14.5% and 14.8% of isolates in Western and Eastern Europe, respectively, 
but to only 5.1% of isolates in North America.  
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 Patients with ICU-acquired infections (n=764) were younger, more likely to be surgical 
admissions, and had lower SAPS II and SOFA scores on admission to the ICU, compared to those who 
had infections within the first 48 hours on the ICU (Table 3 and Table E2). Respiratory and catheter-
associated infections were more frequent and abdominal infections less frequent in patients with 
ICU-acquired than in those with non-ICU-acquired infections (Table E2). Patients with ICU-acquired 
infections were more likely to have positive isolates than patients with non-ICU-acquired infections 
(79.5% vs 66.2%, p<0.001) (Table E3).  
       
Outcomes 
ICU mortality rates were 25.8% in patients with sepsis and 12.1% in those without (p<0.001); hospital 
mortality rates were 35.3 vs. 16.7%, p<0.001). ICU and hospital mortality rates varied from 11.9 and 
19.3% (Oceania) to 39.5 and 47.2% (Africa), respectively (Table 2). ICU length of stay was longer (6 [3-
13] vs. 2 [1-4] days, p<0.001) in patients with than in those without sepsis. As expected, there was a 
stepwise increase in ICU and hospital mortality rates according to the severity of sepsis (Table 3). 
Although patients with ICU-acquired sepsis had longer ICU stays than those who had sepsis within 48 
hours of admission to the ICU, they did not have higher mortality rates (Table 3).  
The crude risk of in-hospital death was higher in patients with infections caused by 
Pseudomonas spp, Acinetobacter spp. and fungi (Table 4). In the multilevel analysis, independent risk 
factors for in-hospital death in patients with sepsis were older age, higher SAPS II score, cirrhosis, 
metastatic cancer, chronic heart failure (NYHA III/IV), use of mechanical ventilation or renal 
replacement therapy at any time during the ICU stay, and infection with Acinetobacter spp. (Table 
E4). The use of mechanical ventilation and presence of comorbid cirrhosis more than doubled the 
risk of death. The relative risk of death was higher in patients admitted to ICUs in countries with 
upper middle GNI than in those with high GNI (1.77 [1.31-2.39, p<0.001). However, although the 
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model suggested significant between-hospital variation (var=0·28, p=0·001) in the individual risk of 
in-hospital death, the between-country variation was not significant.          
 
Discussion 
The present audit confirms the considerable burden that sepsis presents in modern ICUs. This large 
study, including more than 10,000 patients from 730 ICUs, indicates that about 30% of all ICU 
patients have sepsis, as defined by the presence of infection and organ dysfunction. This percentage 
is identical to that (29.5%) reported in the earlier Sepsis Occurrence in Acutely Ill Patients (SOAP) 
study [1] a large European study that used the same methodology, and in a recent analysis of a large 
UK database [18], but somewhat higher than in some other large studies [4, 5, 19, 20]. In addition to 
possible differences associated with different definitions of sepsis used in the various studies, two 
other major elements may account for these apparent inconsistencies. First, we did not include all 
patients admitted to the ICU, but only critically ill patients, excluding patients admitted to the ICU for 
postoperative surveillance without complications. Second, some studies focused on admission data 
[20]; if we consider only the patients who had sepsis on admission in our study, the rate of sepsis was 
18%. Importantly, the percentage of ICU patients with sepsis varied around the globe, with 
particularly high rates in East and South-East Asia, confirming the high disease burden in this area 
[21, 22]. Although these data were collected in 2012, we believe they are still relevant, especially 
given the general lack of global data in this regard.  
 A strength of the present study compared to studies assessing only sepsis on admission or 
prevalence studies (e.g., EPIC II [2]), is that patients were followed throughout the ICU course, 
enabling evaluation of sepsis that developed during the ICU stay as well as sepsis present on 
admission. Interestingly, patients with ICU-acquired sepsis had similar outcomes to those of patients 
with sepsis on admission and ICU-acquired sepsis was not independently associated with a higher 
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risk of mortality after adjusting for confounders in the multilevel analysis. Although we were unable 
to assess this specifically, van Vught et al. [23] recently reported a low attributable mortality of ICU-
acquired infections. Shankar-Hari et al. [24] reported that the inferred causal link between sepsis and 
long-term mortality was significantly confounded by age, comorbidity and pre-acute illness 
trajectory. Importantly, in our multivariable regression analysis all the above mentioned factors were 
found to be significant determinants of mortality, suggesting that ICU-acquired sepsis may not on its 
own be a causative factor for mortality. Nevertheless, nosocomial infections are responsible for 
prolonged stays in the ICU and increased costs [25, 26].  
 Positive isolates were obtained in 70% of the patients with sepsis, a similar finding to that 
reported in other studies [1, 19, 27, 28]. Two thirds of these patients had Gram-negative organisms 
isolated and one half had Gram-positive organisms isolated. The most common Gram-negative 
microorganisms recovered were E. coli, Klebsiella spp., Pseudomonas spp. and Acinetobacter spp., as 
in previous studies [1, 27, 28]. Interestingly, Gram-positive organisms were more common in North 
America than in other parts of the world; MRSA was also more common in North America than in 
other parts of the world except the Middle East. These findings are important when using guidelines 
for management of infection and sepsis, as guidelines developed in one part of the world, for 
example North America, may not be relevant to other areas. The results also underline the ongoing 
importance of fungal infections, which were involved in 13% of cases of sepsis overall, although the 
frequency was lower in the US (5%), perhaps because more stringent criteria are used to characterize 
fungal infections in the US. Finally it is noteworthy that nearly 42% of patients without sepsis 
received antimicrobial agents. The reasons for this are unclear, but antimicrobials may still be 
prescribed despite sepsis resolution or exclusion. In a retrospective analysis of 269 patients who 
were diagnosed with suspected sepsis in the emergency department and started on antibiotic 
therapy, 29% of the patients were found not to have bacterial disease, but the median duration of 
antibiotics in these patients was still seven days (IQR 4-10) [29].     
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 ICU mortality rates in patients with sepsis were around 26% and were twice as high as those 
in non-septic patients. This percentage is lower than the 32% observed in the SOAP study (using their 
“severe sepsis” definition that is equivalent to our current definition of sepsis) [1]  and in other 
studies [1, 19, 27, 28]. ICU mortality rates in patients with septic shock were around 35%, a 
percentage that is also lower than that reported in earlier studies [1, 5]. Increased awareness of 
sepsis diagnosis and improved early management may have contributed to improved outcomes over 
time. Mortality rates varied around the globe, but in multivariable analysis, the between-country 
variation was not significant. These findings are in contrast to those from the International 
Multicenter Prevalence Study on Sepsis (IMPreSS) study of 1794 patients with sepsis from 62 
countries, in which mortality rates were higher in East Europe and Central/South America compared 
to North America after adjustment for adjusted for ICU admission, sepsis status, location of 
diagnosis, origin of sepsis, APACHE II score and country [30].    
 As expected, non-survivors were older and had more comorbidities. As in previous ICU 
studies [1, 2], Pseudomonas and fungal infections were associated with worse outcomes, although 
only Acinetobacter infection was an independent predictor for hospital death in the multilevel 
analysis. Importantly, our data do not infer a cause-effect relationship and the presence of 
Acinetobacter may simply be a marker of severity. In a systematic review of 6 matched case-control 
and cohort studies, Falagas et al. [31] reported that Acinetobacter infection was associated with 
increased attributable mortality, although others have suggested no independent link between 
Acinetobacter infection and increased risk of death [32].  
 Mechanical ventilation at any time during the ICU stay and pre-existing liver cirrhosis were 
also important prognostic factors, more than doubling the risk of death. Use of renal replacement 
therapy at any time during the ICU stay was also associated with increased mortality. We also 
identified significant between-center variation suggesting that differences in local ICU organization 
may impact on outcomes of patients with sepsis. Some of the potential factors associated with 
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between-center outcomes differences have been identified in the literature. In an international 
cohort of 13,796 ICU patients, Sakr et al. reported that a high nurse:patient ratio was independently 
associated with a lower risk of in-hospital death [33]. Gaieski and colleagues reported that sepsis 
outcomes were improved in centres with higher sepsis case volumes [34]. In a multicentre study in 
Canada, Yergens et al. reported that ICU occupancy > 90 % was associated with an increase in 
hospital mortality in patients with sepsis admitted from the emergency department [35]. We are 
unable to identify which particular organizational factors may have influenced outcomes from our 
data and this is an area that needs further study. 
 Our database was very large, including considerable data on demographics, organ function 
and outcomes. Nevertheless, to successfully collect a large amount of data in many ICUs requires 
some limitations in the level of detail of the collected data, and we did not, therefore, collect precise 
information on all subtypes of microorganisms or their resistance patterns or on the appropriateness 
of antimicrobial coverage. Moreover, data were collected by ICU doctors or research nurses who may 
not have specific expertise in infectious diseases although the significance of this is uncertain. Our 
study has other limitations. First, although the audit included a large number of ICUs, the purely 
voluntary nature of the participation may impact on the representativeness of the data. Second, data 
collection was not monitored so that small errors could not be corrected; only obvious incongruous 
data were verified. Third, in some countries, identification of microorganisms may have been 
incomplete because of the limited availability of microbiological testing. Moreover, the quality of the 
antimicrobials used in the treatment of infection has also been questioned in low-resource countries 
[36]. Fourth, there was no means of differentiating between colonization and infection for some 
organisms, including Acinetobacter and coagulase-negative staphylococci. Microorganisms were 
therefore weighted equally in the multilevel analysis. The absence of comparative large 
epidemiologic data that address this issue make it difficult to judge whether the estimates of 
microorganisms provided in our study overestimate the frequency of these infections or not. Fifth, 
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data were collected for the same period in all regions and do not therefore take into account any 
possible influence of seasonal variation. Sixth, we did not use the exact recent Sepsis-3 definitions 
[37], which were published after our study, partly because we had no data on the evolution of SOFA 
scores prior to ICU admission and blood lactate levels were not available in all patients. Nevertheless, 
we used a definition based on the presence of organ dysfunction, a key feature of Sepsis-3. Finally, 
despite adjusting for a large number of variables that may influence outcome, the results of the 
multilevel analysis could not take into account other unmeasured variables which may have been of 
potential significance.  
 
Conclusions 
Sepsis, as defined by infection with organ dysfunction, remains a major health problem in ICU 
patients worldwide, associated with high mortality. There is wide variation in sepsis rates, causative 
microorganisms and outcome in ICU patients around the world. A history of liver cirrhosis or 
metastatic cancer, use of mechanical ventilation or renal replacement therapy, and Acinetobacter 
infection were independently associated with an increased risk of in-hospital death. Global 
epidemiological data such as these help increase awareness of sepsis and provide crucial information 
for future healthcare planning. Further studies in this field should be done on a regular basis with 
standardized methodology to ensure the comparability of the results. 
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Table 1. Characteristics of the study cohort on admission to the ICU according to the presence of 
sepsis 
Characteristic All patients 
N=10069 
No sepsis 
N=7096 
Sepsis 
N=2973 
P value 
Age, years, mean ± SD 60.0±18.0 59.4 ±18.4 61.5 ±17.0 <0.001 
Male, n (%)  5973 (60.1) 4177 (59.7) 1796 (61.0) 0.21 
Severity scores, mean ± SD      
       SAPS II score 40.2±18.2 36.4 ±17.4 49.2 ±16.6 <0.001 
       SOFA score 5 [3-9] 4 [2-7] 8 [6-11] <0.001 
Type of admission, n (%)    <0.001 
   Surgical  3432 (36.0) 2475 (37.0) 957 (33.7)  
   Medical 5382 (56.5) 3646 (54.6) 1736 (61.1)  
   Trauma                643 (6.8) 512 (7.7) 131 (4.6)  
   Other 66 (0.7) 49 (.7) 17 (.6)  
Source of admission, n (%)    <0.001 
   ER/ambulance 3814 (37.9) 2780 (39.2) 1034 (34.8)  
   Hospital floor 2625 (26.1) 1664 (23.4) 961 (32.3)  
   OR/recovery 1811 (18.0) 1363 (19.2) 448 (15.1)  
   Other hospital 981 (9.7) 652 (9.2) 329 (11.1)  
   Other 838 (8.3) 637 (9.0) 201 (6.8)  
Comorbidities, n (%)     
COPD 1240 (12.3) 788 (11.1) 452 (15.2) <0.001 
Cancer 1049 (10.4) 710 (10.0) 339 (11.4) 0.04 
Diabetes mellitus, insulin-dependent  972 (9.7) 664 (9.4) 308 (10.4) 0.12 
Heart failure, NYHA III/IV 921 (9.1) 588 (8.3) 333 (11.2) <0.001 
Chronic renal failure 912 (9.1) 582 (8.2) 330 (11.1) <0.001 
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Cirrhosis 349 (3.5) 217 (3.1) 132 (4.4) <0.001 
Immunosuppression 346 (3.4) 177 (2.5) 169 (5.7) <0.001 
Metastatic cancer 332 (3.3) 221 (3.1) 111 (3.7) 0.11 
Haematologic cancer 212 (2.1) 99 (1.4) 113 (3.8) <0.001 
HIV infection 71 (.7) 37 (.5) 34 (1.1) <0.001 
Number of comorbidities, n (%)    <0.001 
    None 5512 (54.7) 4145 (58.4) 1367 (46.0)  
    1 2800 (27.8) 1880 (26.5) 920 (30.9)  
    2 1207 (12.0) 740 (10.4) 467 (15.7)  
    3 416 (4.1) 249 (3.5) 167 (5.6)  
   >4 134 (1.3) 82 (1.2) 52 (1.7)  
Procedures, n (%)     
    Mechanical ventilation 4776 (47.4) 2755 (38.8) 2021 (68.0) <0.001 
    Renal replacement therapy 537 (5.3) 264 (3.7) 273 (9.2) <0.001 
Antimicrobials, n (%) 5975 (59.3) 3002 (42.3) 2973 (100) <0.001 
    Antibiotic 5935 (58.9) 2979 (42.0) 2956 (99.4) <0.001 
    Antifungal 784 (7.8) 202 (2.8) 582 (19.6) <0.001 
    Antiviral 273 (2.7) 80 (1.1) 193 (6.5) <0.001 
Valid percentages are given after exclusion of missing values (data missing from 546 patients for type of 
admission). COPD: chronic obstructive pulmonary disease, HIV: human immunodeficiency viral infection, ICU: 
intensive care unit, NYHA: New York Heart Association Classification, SAPS: simplified acute physiology, SOFA: 
sequential organ assessment, SD: standard deviation, ER: emergency room, OR: operating room. 
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Table 2. Distribution of the most common microorganisms in patients with positive isolates and mortality rates according to geographic region 
 All patients Western 
Europe 
Eastern  
Europe 
South 
America 
North 
America 
East & 
southeast Asia 
South  
Asia 
Oceania Middle 
East  
Africa 
Total number of patients, n  10069 4335 1110 993 730 946 982 439 393 141 
Patients with sepsis, n (%)
 
2973 (29.5) 1357 (31.3) 336 (30.3) 303 (30.5) 147 (20.1) 372 (39.3) 134 (13.6) 135 (30.8) 151 (38.4) 38 (27.0) 
   Patients with positive isolates, n (%)
a 
2069 (69.6) 947 (69.8) 256 (76.2) 186 (61.4) 117 (79.6) 240 (64.5) 84 (62.7) 105 (77.8) 118 (78.1) 16 (42.1) 
   Gram-positive, n (%) 1030 (49.8) 517 (54.6) 144 (56.3) 84 (45.2) 59 (50.4) 86 (35.8) 18 (21.4) 57 (54.3) 58 (49.2) 7 (43.8) 
     Methicillin-sensitive Staphylococcus aureus  257 (12.4) 120 (12.7) 37 (14.5) 29 (15.6) 14 (12.0) 25 (10.4) 6 (7.1) 14 (13.3) 10 (8.5) 2 (12.5) 
     Methicillin-resistant Staphylococcus aureus (MRSA) 151 (7.3) 58 (6.1) 20 (7.8) 15 (8.1) 15 (12.8) 14 (5.8) 2 (2.4) 9 (8.6) 17 (14.4) 1 (6.3) 
     Coagulase-negative Staphylococcus  500 (24.2) 269 (28.4) 79 (30.9) 39 (21.0) 25 (21.4) 25 (10.4) 11 (13.1) 19 (18.1) 27 (22.9) 6 (37.5) 
     Streptococcus, D group 84 (4.1) 52 (5.5) 10 (3.9) 5 (2.7) 5 (4.3) 3 (1.3) - 6 (5.7) 3 (2.5) - 
     Streptococcus, Others 222 (10.7) 109 (11.5) 25 (9.8) 12 (6.5) 15 (12.8) 27 (11.3) 1 (1.2) 15 (14.3) 16 (13.6) 2 (12.5) 
     Other Gram-positive cocci  46 (2.2) 19 (2.0) 11 (4.3) - 3 (2.6) 7 (2.9) - 4 (3.8) 2 (1.7) - 
 
   Gram-negative, n (%) 1389 (67.1) 610 (64.4) 189 (73.8) 140 (75.3) 65 (55.6) 159 (66.3) 67 (79.8) 66 (62.9) 84 (71.2) 9 (56.3) 
     E. coli 470 (22.7) 236 (24.9) 57 (22.3) 51 (27.4) 22 (18.8) 35 (14.6) 22 (26.2) 25 (23.8) 19 (16.1) 3 (18.8) 
    Klebsiella spp. 356 (17.2) 124 (13.1) 73 (28.5) 46 (24.7) 13 (11.1) 45 (18.8) 18 (21.4) 13 (12.4) 19 (16.1) 5 (31.3) 
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    Pseudomonas spp. 337 (16.3) 147 (15.5) 54 (21.1) 38 (20.4) 18 (15.4) 35 (14.6) 13 (15.5) 12 (11.4) 20 (16.9) - 
    Acinetobacter spp. 243 (11.7) 39 (4.1) 55 (21.5) 36 (19.4) 5 (4.3) 51 (21.3) 24 (28.6) 1 (1.0) 29 (24.6) 3 (18.8) 
    Enterobacter spp. 188 (9.1) 91 (9.6) 45 (17.6) 13 (7.0) 3 (2.6) 11 (4.6) 10 (11.9) 8 (7.6) 5 (4.2) 2 (12.5) 
    Proteus spp. 121 (5.8) 63 (6.7) 25 (9.8) 6 (3.2) 5 (4.3) 7 (2.9) 1 (1.2) 5 (4.8) 6 (5.1) 3 (18.8) 
    Gram-negative, others 320 (15.5) 174 (18.4) 35 (13.7) 20 (10.8) 14 (12.0) 32 (13.3) 4 (4.8) 17 (16.2) 22 (18.6) 2 (12.5) 
  Anaerobes, n (%) 79 (3.8) 45 (4.8) 12 (4.7) 3 (1.6) 8 (6.8) 4 (1.7) - 4 (3.8) 2 (1.7) 1 (6.3) 
  Other bacteria, n (%) 18 (0.9) 4 (0.4) 2 (0.8) 2 (1.1) 1 (0.9) 5 (2.1) 1 (1.2) 2 (1.9) 1 (0.8) - 
  Fungi, n (%) 266 (12.9) 137 (14.5) 38 (14.8) 18 (9.7) 6 (5.1) 31 (12.9) 8 (9.5) 10 (9.5) 16 (13.6) 2 (12.5) 
    Candida albicans 185 (8.9) 93 (9.8) 31 (12.1) 9 (4.8) 3 (2.6) 23 (9.6) 6 (7.1) 9 (8.6) 10 (8.5) 1 (6.3) 
    Candida non-albicans 89 (4.3) 47 (5.0) 8 (3.1) 8 (4.3) 2 (1.7) 11 (4.6) 4 (4.8) 4 (3.8) 4 (3.4) 1 (6.3) 
    Fungi, others 44 (2.1) 28 (3.0) 4 (1.6) 2 (1.1) 1 (0.9) 5 (2.1) - - 4 (3.4) - 
  Viruses and parasites, n (%) 59 (2.9) 31 (3.3) 5 (2.0) 6 (3.2) 2 (1.7) 10 (4.2) - 1 (1.0) 3 (2.5) 1 (6.3) 
Mortality rates in patients with sepsis, n (%) 
   
  
  
   
      ICU 753 (25.8) 309 (22.9) 118 (35.3) 102 (36.3) 27 (18.5) 76 (21.2) 37 (28.9) 16 (11.9) 53 (35.6) 15 (39.5) 
      Hospital 1004 (35.3) 439 (33.3) 146 (44.8) 119 (45.4) 37 (25.2) 108 (31) 44 (35.2) 26 (19.3) 68 (46.6) 17 (47.2) 
a
 in patients with sepsis
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/advance-article-abstract/doi/10.1093/ofid/ofy313/5193171 by guest on 28 N
ovem
ber 2018
Ac
ce
pte
d M
an
us
cri
pt
 
26 
 
Table 3. Severity scores on admission to the ICU, maximum number of organ failure and mortality rates according to sepsis status. 
 
 n  Severity scores, mean ± SD 
SAPS II           SOFA  
ICU LOSa, 
median [IQ] 
No. of organ failures 
Median [IQ] 
Mortality rates, % (95% CI) 
 ICUb In-hospitalc 
Onset of sepsis         
      Within the first 48 hours d 2209 50.5 ± 16.8 9.2 ± 3.9 5 [2-10] 3 [2-4] 26.0 (24.2-27.9) 35.8 (33.8-37.9) 
      Later 764 45.4 ± 15.5‡ 7.5 ± 3.8‡ 12 [6-19]‡ 3 [2-4] 25.1 (22.0-28.3) 33.8 (30.3-37.2) 
Severity of sepsis on ICU admission        
      No sepsisd 8261 37.8 ±17.5 5.3 ±4.1 3 [1-5] 1 [0-2] 13.6 (12.9-14.4) 19.0 (18.1-19.9) 
      Sepsis without shock 822 46.2±15.4‡ 7.4 ±2.9‡ 5 [2-9]‡  2 [1-3]‡ 20.1 (17.4-22.9)‡ 30.3 (27.1-33.6)‡ 
      Septic shock 986 55.1±17.2‡ 11.3 ±3.6‡  5 [2-11]‡  3 [2-4]‡ 33.7 (30.7-36.7)‡ 43.0 (39.9-46.2)‡ 
Severity of sepsis during ICU stay        
      No sepsisd 7096 36.4±17.4 4.9 ± 4.0 2 [1-4] 1 [0-2] 12.1 (11.3-12.8) 16.7 (15.8-17.6) 
      Sepsis without shock 1292 44.6 ± 15.3‡ 7.0 ± 3.2‡ 6 [3-11]‡ 2 [1-3]‡ 14.3 (12.4-16.2)* 23.6 (21.3-26.0)‡ 
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      Septic shock 1681 52.7 ± 16.7‡ 10.1 ± 3.9‡ 7 [3-14]‡  3 [2-4]‡ 34.6 (32.3-36.9)‡ 44.2 (41.7-46.6)‡ 
ICU LOS: intensive care unit length of stay, IQ: interquartile, SAPS: simplified acute physiology score, SD: Standard deviation, SOFA: sequential organ failure assessment score, 
Missing observations:
 
(a) 489 (b) 401 (c) 797. *: p < 0.05; ‡:  p < 0.01 among groups. (d):  the reference group.
 
 
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/advance-article-abstract/doi/10.1093/ofid/ofy313/5193171 by guest on 28 N
ovem
ber 2018
Ac
ce
pte
d M
an
us
cri
pt
 
28 
 
Table 4. Outcome according to isolated microorganisms in patients with sepsis (n=2973) 
  
ICU mortality,  
n (%) 
Hospital 
mortality, n (%) 
Crude risk of in- 
hospital death 
OR (95% CI) 
 
p-value 
 
Gram-positive 267 (26.2) 360 (36.0) 1.05 (0.89-1.23) 0.55 
     Staphylococcus aureus methicillin-
sensitive 
71 (28.0) 89 (36.0) 1.04 (0.79-1.36) 0.80 
    MRSA 36 (24.2) 51 (34.7) 0.97 (0.69-1.38) 0.87 
    Staphylococcus, coagulase negative 129 (26.0) 184 (37.9) 1.14 (0.93-1.40) 0.20 
    Streptococcus, D group 16 (19.3) 22 (27.5) 0.69 (0.42-1.13) 0.14 
    Streptococcus, others 57 (26.1) 77 (35.8) 1.02 (0.77-1.37) 0.87 
    Other Gram-positive cocci  9 (19.6) 13 (29.5) 0.77 (0.40-1.47) 0.42 
Gram-negative 364 (26.6) 492 (37.0) 1.15 (0.99-1.34) 0.07 
     E. coli 114 (24.7) 162 (36.0) 1.04 (0.84-1.28) 0.74 
     Enterobacter spp. 45 (24.1) 67 (36.8) 1.07 (0.79-1.46) 0.66 
    Klebsiella spp. 92 (26.4) 128 (37.9) 1.13 (0.90-1.43) 0.29 
    Acinetobacter spp. 88 (37.0) 110 (48.0) 1.78 (1.36-2.33) <0.01 
    Proteus spp. 28 (23.1) 40 (33.6) 0.92 (0.63-1.36) 0.69 
    Pseudomonas spp. 100 (30.1) 131 (40.4) 1.28 (1.01-1.62) 0.04 
    Gram-negative, others 82 (25.9) 110 (35.7) 1.02 (0.80-1.31) 0.87 
Anaerobes 23 (29.1) 31 (39.7) 1.22 (0.77-1.93) 0.41 
Other bacteria 6 (33.3) 7 (38.9) 1.17 (0.45-3.02) 0.75 
Fungi 77 (29.2) 107 (41.6) 1.34 (1.04-1.75) 0.03 
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    Candida albicans 49 (26.8) 71 (39.9) 1.23 (0.90-1.68) 0.19 
    Candida non-albicans 26 (29.2) 38 (43.7) 1.44 (0.93-2.21) 0.10 
    Fungi, others 16 (36.4) 20 (45.5) 1.54 (0.85-2.80) 0.16 
Viruses and parasites 16 (28.1) 21 (36.8) 1.07 (0.62-1.84) 0.81 
 
MRSA: methicillin-resistant Staphylococcus aureus 
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 Figure 1. Distribution of patients according to the presence or absence of sepsis on admission and 
during the ICU stay 
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